title: Prevention of breast cancer by recapitulation of pregnancy hormone levels.
abstract: At the present time, the only approved method of breast cancer prevention is use of the selective estrogen receptor modulator (SERM) tamoxifen. Many breast cancers are driven to grow by estrogen, and tamoxifen exploits this by blocking estrogen action at the estrogen receptor. A counter-intuitive and controversial approach to breast cancer prevention is administration of estrogen and progestin at an early age to achieve pregnancy levels. This approach is supported by the fact that breast cancer incidence is halved by early (< or = 20 years of age) full-term pregnancy. Moreover, it has been demonstrated in rodent models that mimicking the hormonal milieu can effectively prevent carcinogen-induced mammary cancer. In this issue of Breast Cancer Research Rajkumar and colleagues use the rodent model to further define the timing and type of hormonal therapy that is effective in preventing mammary carcinogenesis. Clearly, application of this approach in humans may be difficult, but the potential benefit is intriguing.
authors.affiliation: Department of Biopharmaceutical Sciences, College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois, USA. dtonetti@uic.edu
authors.forename: Debra A
authors.initials: DA
authors.lastname: Tonetti
mesh_terms: D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000097:blood / Q000517:prevention & control; D004967:Estrogens / Q000008:administration & dosage / Q000097:blood; D005260:Female; D006801:Humans; D015674:Mammary Neoplasms, Animal / Q000139:chemically induced / Q000517:prevention & control*; D011247:Pregnancy; D011372:Progestins / Q000008:administration & dosage / Q000097:blood; D051381:Rats; D011917:Rats, Inbred Lew; D013997:Time Factors
chemical_list: D004967:Estrogens; D011372:Progestins